ACM
CYTK icon

Altium Capital Management’s Cytokinetics CYTK Stock Holding History

Altium Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-20,000
Closed -$1.67M – 79
2023
Q4 		$1.67M Buy
+20,000
New +$724K 1.13% 24
2021
Q3 		– Sell
-84,262
Closed -$1.67M – 130
2021
Q2 		$1.67M Sell
84,262
-19,000
-18% -$446K 0.39% 92
2021
Q1 		$2.4M Buy
+103,262
New +$2.2M 0.67% 65

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Altium Capital Management's CYTK Position: Q1 2024 in Review

Altium Capital Management sold out of Cytokinetics (CYTK) in Q1 2024, closing a stake of 20,000 shares — an estimated $1.67M sold.

Altium Capital Management first reported a position in CYTK in Q1 2021 and held it in 3 quarters. The position peaked at $2.4M in Q1 2021. 390 funds tracked by Wall St. Rank hold CYTK as of Q1 2024.

  • Altium Capital Management reported no remaining Cytokinetics position as of Q1 2024 after selling out during the quarter.
  • Altium Capital Management sold 20,000 Cytokinetics shares in Q1 2024, an estimated $1.67M.
  • Altium Capital Management first reported a position in Cytokinetics in Q1 2021 and held it in 3 quarters.
  • Altium Capital Management's Cytokinetics position peaked at $2.4M in Q1 2021.
  • 390 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2024.

Based on Altium Capital Management's 13F filing for Q1 2024, filed 15 May 2024.